Asthma Therapeutics: Past, Present, and Future
Pharmacological Reviews,
Год журнала:
2025,
Номер
77(4), С. 100062 - 100062
Опубликована: Апрель 28, 2025
Asthma
is
a
disease
of
airway
inflammation
and
bronchial
hyperresponsiveness
affecting
over
300
million
individuals
worldwide.
Although
described
as
early
460
BC,
the
recognition
asthma
disease,
development
implementation
therapies
to
control
it,
emerged
in
1900s.
The
subsequent
century
introduced
utilization
immunotherapy,
inhaled
medications,
anti-inflammatory
corticosteroids
for
control.
Since
beginning
21st
century,
however,
emergence
novel
pharmacotherapies
has
accelerated
greatly.
Our
understanding
various
phenotypes
their
underlying
mechanisms
(endotypes)
crystallized,
leading
an
era
precision
medicine.
Management
strategies
increasingly
use
targeted
biologic
medications
aimed
at
interrupting
key
components
inflammatory
cascade.
Monoclonal
antibodies
targeting
IgE,
thymic
stromal
lymphopoietin,
or
interleukin-4,
-5,
-13
pathways
have
revolutionized
care
we
provide
our
patients,
resulting
reduction
exacerbations
oral
corticosteroid
(OCS)
dose,
while
improving
lung
function
asthma-related
quality
life.
they
are
able
relief
many
sufferers
severe
even
remission
some,
these
still
infancy.
Because
roles
become
further
established,
new
therapeutic
targets
modalities
offer
significant
promise
greater
personalized
medicine
approach.
This
review
addresses
historical
standard-of-care
treatment,
current
recommendations,
glimpse
into
future
that
likely
help
millions
SIGNIFICANCE
STATEMENT:
affects
hundreds
In
last
few
decades,
treatment
paradigms
transformed
from
recommendations
bronchodilatory
inhalation-based
including
beta-agonists,
more
precisely
add-on
employ
monoclonal
addressing
specific
mechanistic
associated
with
patient
characteristics.
Future
extent
approaches
improve
health
life
those
suffering
asthma.
Язык: Английский
Relationship between pediatric asthma and respiratory microbiota, intestinal microbiota: a narrative review
Frontiers in Microbiology,
Год журнала:
2025,
Номер
16
Опубликована: Май 9, 2025
Pediatric
asthma
is
a
common
chronic
airway
inflammatory
disease
that
begins
in
childhood
and
its
impact
persists
throughout
all
age
stages
of
patients.
With
the
continuous
progress
detection
technologies,
numerous
studies
have
firmly
demonstrated
gut
microbiota
respiratory
are
closely
related
to
occurrence
development
asthma,
research
increasing
day
by
day.
This
article
elaborates
detail
on
characteristics,
composition
normal
lung
at
different
ages
sites,
as
well
connection
gut—lung
axis.
Subsequently,
it
deeply
analyzes
various
factors
influencing
colonization,
including
host
factor,
delivery
mode,
maternal
dietary
infant
feeding
patterns,
environmental
microbial
exposure
pollutants,
use
antibiotics
early
life.
These
highly
likely
play
crucial
role
onset
process
progression
asthma.
Research
shows
obvious
changes
occurred
patients,
these
microbiomes
exhibit
characteristics
according
phenotypes
endotypes
Finally,
summarizes
microbiota—related
treatment
approaches
for
carried
out
recent
years,
application
probiotics,
nutritional
interventions,
fecal
transplantation.
modalities
expected
become
new
directions
future
bring
hope
solving
problem
Язык: Английский